CHICAGO, May 31, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that ivonescimab, the Company's first-in-class PD-1/VEGF bispecific antibody, has achieved a ...

Summit Therapeutics Inc. (NASDAQ: SMMT) today announced positive overall survival (OS) results from the Phase III HARMONi-6 trial, conducted in China and sponsored by Summit’s partner Akeso, Inc.

Three Poster Presentations Will Feature Updated Ivonescimab Data, including Intracranial Anti-Tumor Activity from the Global HARMONi Phase III Study The first poster, “Intracranial Efficacy of ...

Ivonescimab plus chemotherapy helped patients with advanced squamous NSCLC live longer than tislelizumab plus chemotherapy. Patients with previously untreated advanced squamous non-small cell lung ...

Matthew Herper covers medical innovation — both its promise and its perils. CHICAGO — Ivonescimab, a drug that combines the activity of two of the best-selling cancer medicines, reduced the risk of ...

CHICAGO -- A first-in-class bispecific antibody targeting PD-1 and VEGF combined with chemotherapy significantly improved overall survival (OS) in patients with advanced squamous non-small cell lung ...

・New ASCO data boosted the case for Ivonescimab as a potential challenger to Merck's blockbuster cancer drug Keytruda. ・Phase 3 Harmoni-6 data showed that Ivonescimab plus chemotherapy extended ...

Bevacizumab plus encorafenib-cetuximab in BRAF V600E mutated metastatic colorectal cancer (mCRC): A phase II study with a safety lead-in cohort (the BRAVE trial). This is an ASCO Meeting Abstract from ...

HARMONi-6 Demonstrates Significant Overall Survival Benefit (HR=0.66): Ivonescimab Plus Chemotherapy Superior to PD-1 Plus Chemotherapy in First-Line sq-NSCLC Landmark Results to Be Presented at ASCO ...

Unfortunately you've used all of your gifts this month. Your counter will reset on the first day of next month. CHICAGO, May 31, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") ...